Frank Beier
Merck KGaA
23 Papers
173 Citations
Frank Beier is an academic researcher from Merck KGaA. The author has contributed to research in topics: Cetuximab & FOLFIRI. The author has an hindex of 12, co-authored 23 publications. Previous affiliations of Frank Beier include University of Southern California.
Chat about Author
Papers
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Eric Van Cutsem,Heinz-Josef Lenz,Claus Henning Köhne,Volker Heinemann,Sabine Tejpar,Ivan Melezínek,Frank Beier,Christopher Stroh,Philippe Rougier,J. Han van Krieken,Fortunato Ciardiello +10 more
TL;DR: It is demonstrated that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival, progression-free survival, and objective response in the first-line treatment of patients with KRAS codon 12/13 (exon 2) wild-type metastatic colorectal cancer.
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
Sabine Tejpar,Sebastian Stintzing,Fortunato Ciardiello,Josep Tabernero,Eric Van Cutsem,Frank Beier,Regina Esser,Heinz-Josef Lenz,Volker Heinemann +8 more
TL;DR: Patients with left-sided tumors had a markedly better prognosis than those with right-sided tumor locations and a significant interaction was observed between primary tumor location and treatment for OS within the RAS wt populations of both studies in multivariable models that also included sex, prior adjuvant therapy, and BRAF mutational status.
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
Carsten Bokemeyer,C.-H. Köhne,Fortunato Ciardiello,H. J. Lenz,Volker Heinemann,Ute Klinkhardt,Frank Beier,Klaus Duecker,J.H.J.M. van Krieken,Sabine Tejpar +9 more
TL;DR: Patients with RAS-mutant mCRC, as defined by mutations in KRAS and NRAS exons 2-4, derive no benefit and may be harmed by the addition of cetuximab to FOLFOX4, reports outcomes in subgroups defined by extended RAS testing.
235
Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
Jan B. Vermorken,Amanda Psyrri,Ricard Mesia,Frederic Peyrade,Frank Beier,B. de Blas,Ilhan Celik,Lisa Licitra +7 more
TL;DR: Adding cetuximab to chemotherapy improved survival in patients with recurrent/metastatic squamous cell carcinoma of the head and neck and this pattern remained in a combined analysis of both p16 and HPV and in Patients with oropharyngeal cancer separately.
204
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
Charles Butts,Andrew Maksymiuk,Glenwood D. Goss,Denis Soulières,Ernie Marshall,Yvon Cormier,Peter M. Ellis,Allan Price,Ravinder Sawhney,Frank Beier,Martin H. Falk,Nevin Murray +11 more
TL;DR: Confirming the initial results, further follow-up continues to show that survival time for patients with stage IIIB/IV NSCLC was longer with L-BLP25 plus BSC compared with BSC alone, with the greatest difference seen in patients withStage IIIB LR disease.
195